Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Fibrocell Science, Inc.

by

Fibrocell Science is a US public company that develops personalized autologous cell therapies for aesthetic, medical and scientific applications. It raised $9.3 million in a secondary public offering, as reported in the PharmSource Lead Sheet on December 14, 2017.

Corporate Highlights

  • Fibrocell Science was incorporated in Delaware in September 1992.
  • Corporate Headquarters: Exton, PA
  • As of December 31,2016, they had 23 employees
  • Stock Exchange: NASDAQ
  • Stock Symbol: FCSC

Sourcing Opportunities

  • Fibrocell Science plans to use the proceeds to continue clinical and preclinical development of FCX-013 and FCX-007:
  • FCX-013 : To complete preclinical studies:
    • For treatment of localized scleroderma
    • Dosage Form: Parenteral
    • Nature of API: Biologic – Manipulated/Transplanted cells
    • Therapeutic Areas: Dermatology; Pediatric; Other
  • FCX-007: To complete a Phase I clinical trial:
    • For treatment of recessive dystrophic epidermolysis bullosa
    • Dosage Form: Parenteral
    • Nature of API: Biologic – Manipulated/Transplanted cells
    • Therapeutic Areas: Dermatology; Pediatric
  • The company contracts with contract research organizations (CROs) to conduct clinical trials.
  • Fibrocell Science does own and operate a manufacturing facility in Exton, PA and also relies on third party contract manufacturers for certain material for FCX-007.
  • Fibrocell Science has no sales, marketing or distribution capabilities or experience.

Business Relationships

  • In January 2016, Fibrocell Science and Intrexon entered into an Exclusive Channel Collaboration agreement for the development of fibroblasts for the treatment of chronic inflammatory and degenerative diseases of the joint. Under the terms of the agreement, Fibrocell Science paid $10 million for R&D costs and up to $52.5 million contingent upon regulatory and commercial milestones.

Pipeline

Product Candidate Indication Dosage Form Status Next Anticipated Step
Gene Therapy Research Program Arthritis and other related conditions Unknown Discovery TBA
FCX-013 Localized Scleroderma Parenteral Preclinical TBA
FCX-007 Recessive Dystrophic Epidermolysis Bullosa Parenteral Phase I TBA

Finance

(In $ thousands) 2016 2015
Revenue 355 492
R&D Expenditures 8,400 9,968
General & Administrative Expenditures 9,773 11,285
Total Operating Expenses 18,528 21,745

Contact Information

Fibrocell Science, Inc.  Key Officers
405 Eagleview Blvd.  John Maslowski, CEO
Exton, PA, 19341 USA Melissa Newman, Director, QC Microbiology
Phone:  +1-484-713-6000 Liz McDaniel Murray, Manager, Clinical Trials
Fax: +1-484-713-6001 Pamela Swiggard, VP, Regulatory Affairs & QA
Web: http://fibrocell.com/ Elizabeth Browning, EVP, Marketing

Related posts:
Follow the Money to Pharmaceutical Opportunities – Spotlight on Fusion Pharmaceuticals, Inc.
Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.

Follow the Money to Pharmaceutical Opportunities – Spotlight on CymaBay Therapeutics

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu